This year’s Diabetes Awareness Week (13-19 June) is celebrating the triumphs and challenges for all people with diabetes. To celebrate the week, as well as the updated NICE (National Institute of Health and Care Excellence) guidelines, which will allow more people than ever before have access to modern diabetes management technology, Dexcom is hosting its … [Read more…]
SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News: Median Technologies (ALMDT) announces today the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies. In the initiation report published on June 10, 2022, Bryan Garnier & Co initiates the coverage of the stock with a buy recommendation and values the … [Read more…]
— Data presented at ENDO 2022 indicates low rates of hyperglycemic events were easily controlled, did not cause treatment disruption and were most often seen in patients with pre-existing diabetes — — A separate poster presentation examined response to TEPEZZA in patients who were mildly hypothyroid and found outcomes were consistent with those in the … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that additional data from its preclinical program to develop OR-449 for the treatment of adrenocortical cancer (ACC) was presented at the 104th Annual Meeting of the Endocrine Society … [Read more…]
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell therapy Total patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 percent; CAR T-naïve patients achieved 69 percent ORR and 42 percent CR; patients previously … [Read more…]
– Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure – – Safety profile generally consistent with myeloablative conditioning and autologous stem cell transplant – BOSTON & ZUG, Switzerland & … [Read more…]
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium Data support potential of quizartinib as targeted therapy for aggressive FLT3-ITD subtype of AML TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Positive results from the global pivotal QuANTUM-First phase 3 trial of Daiichi Sankyo’s (TSE:5468) quizartinib combined with standard induction and consolidation chemotherapy … [Read more…]
Rapid and potent C5 inhibition achieved with complete and sustained blockage of complement by a single dose of CAN106 Data to be presented at the 14th International Conference on Complement Therapeutics BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals Inc. (HKEX:1228) , a China and US-based global biopharmaceutical company committed to the research, development and commercialization of … [Read more…]
Both studies met their primary endpoints with significantly higher response than placebo after one month for both frown lines and crow’s feet Results showed rapid onset of action with median response within two days (39% saw results on Day 1 for frown lines and 34% on Day 1 for crow’s feet) Results also demonstrated long … [Read more…]
First FDA-cleared tool to assist clinicians in diagnosing and assessing autism spectrum disorder (ASD) in children as young as 16 months old ATLANTA–(BUSINESS WIRE)–EarliTec Diagnostics, Inc. (“EarliTec”), a digital health company developing novel diagnostic and therapeutic products for children with autism spectrum disorder (ASD) and early childhood vulnerabilities, today announced U.S. Food and Drug Administration … [Read more…]
